fda warning letters glp-1 compounders september 2025 news Trends In FY FDA Issues Warning Letters to

Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DK

[DOI] [PMC free article] [PubMed] [Google Scholar] 179.Parker HE, Reimann F, Gribble FM

PS: Data curation, Writing original draft, Writing review & editing

Arguments for Game Changer Status Several compelling arguments support the characterization of GLP-1 agonists as transformative therapies: Unprecedented Efficacy : Tirzepatide marks a new era in overweight/obesity treatment, enabling many to achieve 20% weight loss [76] [77]

Qualifying comorbidities include type 2 diabetes, hypertension, dyslipidemia (abnormal cholesterol levels), and obstructive sleep apnea

However, several studies have demonstrated alterations in anorexigenic and orexigenic hormones in patients with PWS relative to obese individuals (Fig